American Journal of Epidemiology Vol. 148, No. 4: 350-354
Copyright © 1998 by The Johns Hopkins University School of Hygiene and Public Health
other |
No Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease
1Department of Medicine, Department of Veteran Affairs Medical Center Nashville, TN
2Department of Preventive Medicine, Vanderbilt University Nashville, TN
3Department of Medicine, Division of Gastroenterology, Vanderbilt University Nashville, TN
4Department of Medicine, Division of General Internal Medicine, Vanderbilt University Nashville, TN
Reprint requests to Dr. Walter Smalley, A-1128 MCN, VUMC, Nashville, TN 37232.
Calcium channel antagonists are commonly used drugs that have recently been reported to be associated with an increased incidence of gastrointestinal hemorrhage. We performed a retrospective cohort study among 105, 824 enrollees of the Tennessee Medicaid program 65 years of age or older between 1984 and 1986. Exposure to calcium channel blockers and other medications was determined from pharmacy files. Hospitalization for bleeding peptic ulcers was identified by hospital claims and verified by a review of the medical record. Univariate estimates of relative risk for current users of calcium channel blockers and beta-blocker users were 1.8 (95% confidence interval (Cl) 1.2–2.7) and 1.1 (95% Cl 0.7–1.6) (reference group was nonuse of either). After adjustment for potential confounders, the relative risks for bleeding peptic ulcer among current users of calcium channel blockers and beta btockers were 1.1 (95% Cl 0.7–1.7) and 1.0 (95% Cl 0.7–1.6), respectively, when compared with those who used neither drug. In this population, after controlling for important confounders, there was no increased risk for hospitalization with bleeding peptic ulcer among users of calcium channel blockers. Am J Epidemiol 1998; 148:350–4.
antihypertensive agents; calcium channel blockers; gastrointestinal hemorrhage
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Luks and E. R. Swenson Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness Chest, March 1, 2008; 133(3): 744 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H.H. Leenen, C. E. Nwachuku, H. R. Black, W. C. Cushman, B. R. Davis, L. M. Simpson, M. H. Alderman, S. A. Atlas, J. N. Basile, A. B. Cuyjet, et al. Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Hypertension, September 1, 2006; 48(3): 374 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Boulanger, O. Hauch, M. Friedman, T. Foster, D. Dixon, G. Wygant, and J. Menzin Warfarin Exposure and the Risk of Thromboembolic and Major Bleeding Events Among Medicaid Patients with Atrial Fibrillation Ann. Pharmacother., June 1, 2006; 40(6): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Kaplan, S. R. Heckbert, T. D. Koepsell, F. R. Rosendaal, and B. M. Psaty Use of Calcium Channel Blockers and Risk of Hospitalized Gastrointestinal Tract Bleeding Arch Intern Med, June 26, 2000; 160(12): 1849 - 1855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Weil, M J S Langman, P Wainwright, D H Lawson, M Rawlins, R F A Logan, T P Brown, M P Vessey, M Murphy, and D G Colin-Jones Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs Gut, January 1, 2000; 46(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|